Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

6 evidence topics · 5 sources

Summary: anticipated use and care setting

Vonaprument is not approved for any use. In the phase 3 ARCHER II trial it is given as 5.0 mg per eye by monthly intravitreal injection, which places its anticipated use among physician-administered intravitreal therapies, the same route and setting as the two approved complement inhibitors for geographic atrophy, pegcetacoplan and avacincaptad pegol. The AAO Preferred Practice Pattern states that the ophthalmologist should administer all treatment and anti-VEGF injections for AMD. A U.S. expert panel recommends nonurgent referral to a retina specialist for any suspected geographic atrophy and notes that current anti-complement therapy requires “office visits every 1 to 2 months”.

In a footnote that begins “Based on market reports”, the sponsor estimates that approximately 75,000 U.S. patients are actively treated with available therapies, about 10% of the 800,000 people diagnosed with geographic atrophy or under the care of retina specialists and about 5% of an estimated 1.5 million U.S. people with geographic atrophy. Medicare Part B fee-for-service data for 2025 record 32,021 beneficiaries with 168,366 claims for pegcetacoplan and 27,497 beneficiaries with 140,741 claims for avacincaptad pegol, with total spending of about $451.1 million and $364.9 million. For the first quarter of 2026 the counts were 24,179 and 23,315 beneficiaries. No source states a planned price, distribution model, or position in a treatment sequence for vonaprument.